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ABSTRACT
There are currently no robust noninvasive markers of fragility fractures. Secreted frizzled related protein-1 (sFRP-1), dickkopf-related
protein 1 (DKK1) and DKK2, and sclerostin (SOST) inhibit Wnt signaling and interfere with osteoblast-mediated bone formation. We
evaluated associations of serum levels of sFRP-1, DKK1, DKK2, and SOST with incident low-impact fracture and BMD in 828 women
aged 65 years from EpiDoC, a longitudinal population-based cohort. A structured questionnaire during a baseline clinical
appointment assessed prevalent fragility fractures and clinical risk factors (CRFs) for fracture. Blood was collected to measure serum
levels of bone turnover markers and Wnt regulators. Lumbar spine and hip BMD were determined by DXA scanning. Follow-up
assessment was performed through a phone interview; incident fragility fracture was defined by any new self-reported low-impact
fracture. Multivariate Cox proportional hazard models were used to analyze fracture risk adjusted for CRFs and BMD. During a mean
follow-up of 2.3 1.0 years, 62 low-impact fractures were sustained in 58 women. A low serum DKK2 level (per 1 SD decrease) was
associated with a 1.5-fold increase in fracture risk independently of BMD and CRFs. Women in the two lowest DKK2 quartiles had a
fracture incidence rate of 32 per 1000 person-years, whereas women in the two highest quartiles had 14 fragility fractures per 1000
person-years. A high serum sFRP1 level was associated with a 1.6-fold increase in fracture risk adjusted for CRFs, but not
independently of BMD. Serum levels of SOST (r¼ 0.191; p¼ 0.0025) and DKK1(r¼0.1725; p¼ 0.011) were correlated with hip BMD,
but not with incident fragility fracture. These results indicate that serum DKK2 and sFRP1 may predict low-impact fracture. The low
number of incident fractures recorded is a limitation and serum levels of Wnt regulators should be further studied in other
populations as potential noninvasive markers of fragility fractures. © 2019 The Authors JBMR Plus published by Wiley Periodicals, Inc.
on behalf of American Society for Bone and Mineral Research.
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Osteoporosis is a metabolic skeletal disease characterized bylow bone mass and microarchitecture deterioration that
frequently affects older adults.(1,2) The clinical consequence of
osteoporosis is the occurrence of low-impact fractures, resulting in
increased mortality, morbidity, and disability, as well as imposing a
major economic burden on European health care systems.(3,4) One
strategy for preventing osteoporosis-related fractures is to refine
tools for identifying individuals with a high risk of fracture, as almost
half of all fractures occur in individuals who are not classified as high
risk by DXA scanning.(5) To improve fracture risk assessment, several
algorithms have been developed and validated.(6) These include
clinical risk factors (CRFs) such as age, gender, BMI, prior fragility
fracture, parental history of hip fracture, use of oral glucocorticoids,
rheumatoid arthritis, and other secondary causes of osteoporosis,
including current smoking and alcohol intake to predict low-
impact fracture, independently of BMD.(7) Although the perfor-
mance of these fracture risk-prediction tools is good, there is room
for improvement in sensitivity and specificity.(6,8) The clinical
challenge faced today is the accurate selection of individuals with a
high risk of fracture and with indication for treatment to minimize
individual and societal costs.(1,5)
Serum assays for biochemical markers are important for
monitoring alterations in bone formation and resorption, both in
normal physiological conditions and in disease. Bone turnover
markers (BTMs), reflecting bone remodeling,(9) are modestly
associated with fracture risk.(10) However, uncertainty exists
regarding the clinical application of BTMs, as they exhibit short-
and long-term within-subject variability, and their usefulness for
fracture prediction remains to be determined.(11,12) Thus, new
biochemical markers of bone metabolism that better predict
low-impact fracture are needed.
Recent studies show the importance of Wnt signaling to
osteoblast differentiation.(13) The most well-studied secreted Wnt
antagonists are sclerostin (SOST), dickkopfs (DKKs), and secreted
frizzled related proteins (sFRPs), which regulate osteoblast-
mediated bone formation.(14) Some Wnt antagonists have been
considered not only as treatment targets,(15) but also as potential
markers of bone fragility. Serum levels of DKK1 and SOST increase
with age and are associated with low bone mass.(16,17) sFRP-1
overexpression decreases bone density and attenuates the bone
anabolic effects of PTH.(18) DKK2 can either behave as a Wnt
agonist or antagonist, depending on the cellular context.(19) DKK2
inhibits bone formation in the absence of Wnt7b, but induces
terminal osteoblast differentiation in the presence of high Wnt7b
levels.(20) Also, DKK2-null mice are osteopenic with suppressed
bone formation.(21) Currently, however, there are conflicting
results regarding the association between serum levels of DKK1
and SOST and low-impact fractures.(22–26) In addition, to the best
of our knowledge, no studies have addressed the associations of
DKK2 and sFRP-1 with fracture.
The aim of the present study was to evaluate the association
of serum levels of SOST, DKK1, DKK2, and sFRP-1 with BMD, and




This study was conducted as part of the Epidemiology of Chronic
Diseases (EpiDoC) Cohort initiated in 2011. EpiDoC is a prospective
closed cohort study based on a nationally representative sample of
adults (18 years old) who were noninstitutionalized and living in
private households in Portugal Mainland and Islands (Azores and
Madeira). The primary aim of the baseline assessment EpiDoC 1
(EpiReumaPt), which occurred between September 2011 and
December 2013, was to assess rheumatic and musculoskeletal
disease prevalence and burden in Portugal. Multistage random
sampling was used for participant selection. Baseline assessment
consisted of two phases: The first phase involved a face-to-face
interview; the second phase involved a detailed clinical evaluation
of rheumatic and musculoskeletal disease performed by a
rheumatologist. All participants enrolled in EpiDoC 1 (n¼ 10,661)
were invited to participate in the follow-up, of whom 10,153
(95.2%) agreed to participate.
For follow-up waves EpiDoC 2 (2013 to 2015) and EpiDoC 3
(2015 to 2016), data were collected using a structured
questionnaire through phone interviews using a computer-
assisted personal interview system. In each follow-up interview,
research assistants applied a nuclear questionnaire (including
questions on new rheumatic disease onset, new fragility
fractures, falls, medical treatment, and hospitalizations) and
additional questions for each wave depending on its focus.
When a contact was not available, further attempts were made
at varying timepoints (eg, mornings, afternoons, evenings, and
weekends) for a total of six attempts. Attempts were abandoned
only when the last contact attempt occurred at least 1 month
after the previous contact. Rescheduling of the telephone
interview was permitted.
Necessary sample size was calculated considering the primary
aim of EpiDoC 1, which was to determine the prevalence of
rheumatoid arthritis with 95% CIs standardized for age and
gender according to the total adult population of the studied
areas. Assuming an expected prevalence of rheumatoid arthritis
of 0.5% to 1% and a dropout rate of 50%, 9000 participants
needed to be recruited. We recruited 10,661 participants.
Study population
The population of interest for the present study was women
aged 65 years who were observed by rheumatologists during
the second phase of the baseline EpiDoC 1 assessment and
agreed to be followed up in subsequent EpiDoC waves. A full
description of this population is provided elsewhere.(27) Women
under osteoporosis treatment or diagnosed with bone metasta-
sis or other bone metabolic diseases, such as Paget’s disease of
bone, were excluded from this study.
Outcome definition and assessment
Fragility fracture events were defined as any self-reported low-
impact fracture occurring after 40 years of age, including
fractures resulting from a fall from a standing height or sustained
fractures in the absence of trauma.(28,29) Self-reports of fragility
fractures have been shown to be accurate.(30–32) Incident
fractures were defined as self-reported new fractures during
the two follow-up waves. The follow-up period was computed as
time from baseline visit to the report of the first fracture, death,
or the planned study ending, whichever occurred first.
Covariate definition and assessment
CRFs for fracture including age, BMI (calculated using self-
reported weight and height and categorized as underweight¼
<18.5 kg/m2, normal weight¼ 18.5 to 24.9 kg/m2, overweight
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¼ 25 to 29.9 kg/m2, obese¼30 kg/m(2)), parental history of hip
fracture, long-term use of oral glucocorticoids (3 months),
rheumatoid arthritis, current smoking, high alcohol intake (3
units/day), and number of falls in the previous 12 months were
collected at baseline. Secondary osteoporosis was identified if
the participant had a disorder strongly associated with
osteoporosis. These include type I (insulin dependent) diabetes,
osteogenesis imperfecta in adults, untreated long-standing
hyperthyroidism, hypogonadism or premature menopause
(<45 years), chronic malnutrition, or malabsorption and chronic
liver disease.
Self-reported previous fragility fractures (ie, prevalent fragility
fractures) were also recorded at baseline. Ten-year probability of
major hip fracture was calculated using the Fracture Risk
Assessment (FRAX) tool(33) without using hip DXA information.
Physical activity level was classified based on the self-reported
weekly frequency of physical activity: inactive¼<1 hour/week
and active¼1 hour/week.
DXA procedure
All women aged 65 years who attended the second phase of
the baseline assessment were invited to undergo lumbar and
nondominant hip BMD measurement (g/cm2) using DXA
scanning (Hologic QDR 4500 A; Hologic, Bedford, MA, USA).
Quality control procedures were performed according to the
manufacturerś recommendations.
Biochemical assessment
Blood samples were collected at baseline.(34) Serum was
separated by centrifugation (800g for 10 min at room tempera-
ture) and kept at 4 °C. Serum samples were sent to a central
diagnostic laboratory to determine levels of bone remodeling
markers, 25-hydroxyvitamin D3, intact PTH, and creatinine. The
remaining samples were stored at 80 °C at Biobanco-IMM
(Lisbon Academic Medical Centre, Lisbon, Portugal).(34,35)
At the central lab, parameters were measured according to
manufacturers’ instructions. Serum levels of creatinine were
measured using the rate-blanked creatinine method (Dimension
Vista Intelligent Lab System; Siemens Healthcare, Erlangen,
Germany), and the glomerular filtration rate was calculated.(36)
Serum levels of PTH, osteocalcin, crosslinked C-telopeptide of
type I collagen (CTX-I), and amino-terminal propeptides of type I
procollagen (P1NP) were measured using a fully automated
Immulite 2000 electrochemiluminescent immunoassay analyzer
(Siemens Healthcare). Serum levels of 25-hydroxyvitamin D3 were
measured using competitive immunoassay (Liason Analyzer;
DiaSorin, Saluggia, Italy).
Measurement of Wnt signaling pathway regulators
Wnt signaling regulators were measured in serum stored at
Biobanco-IMM(35) in a subsample of women randomly selected.
Baseline serum levels of sFRP-1 (Cloud-Clone Corp., Katy, TX,
USA; intra-assay coefficient of variation [CV]<10%; interassay CV
<12%), DKK2 (Elabscience, Wuhan, China; intra-assay CV <7%;
interassay CV<7%), DKK1 (Biomedica Medizinprodukte, Vienna,
Austria; intra-assay CV 3%; interassay CV <3%), and SOST
(Biomedica Medizinprodukte; intra-assay CV7%; interassay CV
10%) were determined by commercially available ELISA
according to the manufacturers’ instructions and were analyzed
using a Tecan Infinite 200 PRO plate reader (Tecan, M€annedorf,
Switzerland).
Statistical analysis
Data are presented as mean SD or frequency and proportion
unless stated otherwise. Baseline characteristics of participants
with and without incident fragility fracture were compared
using univariable logistic regression analysis. Associations
between serum levels of Wnt signaling regulators (sFRP-1,
DKK2, DKK1, and SOST) were analyzed using Pearson correla-
tions. Associations between serum levels of Wnt signaling
regulators and continuous or T-score categories of axial BMD
(lumbar and nondominant hip) were also analyzed using
Pearson correlations. Associations between serum levels of
Wnt signaling regulators and BMD were analyzed by univariable
linear regression and adjusted for age, BMI, family history of hip
fracture, physical activity, and glucocorticoid use. Associations
between serum levels of Wnt signaling regulators and incident
fragility fracture were analyzed using Cox’s proportional hazard
models with serum levels of Wnt signaling regulators as
continuous or standardized (per 1 SD) measures. Fracture risk
estimates were adjusted for age, family history of hip fracture,
and prevalent fragility fracture. Adjustment for lumbar and hip
BMD was performed in a separate Cox regression model.
To further identify high-risk subgroups of women for incident
fragility fracture, serum levels of DKK2 were categorized into
quartiles and sFRP-1 were categorized into quintiles. To classify
exposure (serum levels of DKK2 and of s-FRP-1) into two
categories, cutpoint selection was decided using a “outcome-
oriented approach” as described by Schulgen and colleagues.(37)
The relationship between DKK2 (ng/mL) quartile (Q1, Q2 versus
Q3, Q4) and incident fracture rate (per 1000 person-years) was
assessed and adjusted for age, family history of hip fracture,
prevalent fragility fracture, and hip BMD. The relationship
between sFRP-1 (ng/mL) quintile (Q1, Q2 versus Q3, Q4, Q5) and
incident fracture rate (per 1000 person-years) was assessed and
adjusted for age, family history of hip fracture, and prevalent
fragility fracture. Using a risk stratification approach, fracture
rate (per 1000 person-years) was calculated considering the
combination of 10-year risk of major fracture Portuguese cutoff
(<11% versus 11%) without BMD and serum level of DKK2
(lowest two quartiles versus highest two quartiles). The FRAX
score cutoff was based on the Portuguese recommendation for
fracture risk prediction.(38)
Statistical significance was established as p< 0.05. All analyses
were performed using Stata IC, version 12 (StataCorp LP, College
Station, TX, USA).
Ethics approval
The EpiDoC Cohort study was approved by the Ethics Committee
of Nova Medical School (Lisbon, Portugal) and the Portuguese
Data Protection Authority (Comiss~ao Nacional de ProteSc~ao de
Dados, Lisbon, Portugal). Written informed consent in accordance
with principles established by the Declaration of Helsinki was
obtained from all participants. Further details related to ethical
issues are described elsewhere.(39)
Results
Of 3877 participants evaluated by a rheumatologist at baseline,
884 were women aged 65 years. After applying exclusion
criteria, 828 women were included in this study (Fig. 1). A small
proportion of women (n¼ 71; 8.57%) had received bisphosph-
onates in the past. During a mean follow-up of 2.3 1.0 years, 62
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fragility fractures were sustained in 58 women. Most incident
fragility fractures (n¼ 51; 82.3%) were nonhip, nonvertebral (ie,
wrist, lower leg, humerus, rib, clavicle, and elbow). Incident hip
or vertebral fractures were reported by 6 (9.7%) and 4 (6.6%)
women, respectively. Senior women with incident fragility
fractures had significantly more prior fractures and had a family
history of hip fractures more frequently. No other CRFs were
associated with incident fragility fracture (Table 1).
Serum levels of sFRP-1, SOST, and DKK1 are associated
with BMD
There was a negative correlation between baseline serum levels
of DKK1 and DKK2 (r¼0.152; p¼ 0.01). No other correlations
were found among serum levels of Wnt regulators (Supplemen-
tary Table S1).
There was no correlation between serum levels of DKK2 and
BMD (Table 2). Serum levels of sFRP-1 and SOST were positively
correlated with lumbar and hip BMD (Table 2). When BMD was
categorized by T score, the positive correlations for both sFRP-1
and SOST were lost, except in the normal BMD group. After
adjusting for age, BMI, family history of hip fracture, physical
activity, and glucocorticoid use, the serum level of sFRP-1 was
positively correlated with lumbar spine BMD (b¼ 0.040,
p< 0.001) and hip BMD (b¼ 0.011, p¼ 0.001; Supplementary
Table S2). Using the same adjustment parameters, SOST levels
were still positively correlated with lumbar spine BMD
(b¼ 0.001, p< 0.001) and negatively correlated with hip BMD
(b¼0.002, p¼ 0.001; Supplementary Table S2).
By contrast, serum levels of DKK1 were negatively correlated
with hip femoral neck BMD. This association remained
significant even after adjusting for CRFs (b¼0.0004,
p¼ 0.008; Supplementary Table S2).
Serum levels of DKK2 and sFRP-1 are independently
associated with incident low-impact fracture
Low serum level of DKK2 was associated with an increased risk of
low-impact fracture in Cox proportional hazard models (Table 3).
This association remained significant after adjusting for
independent CRFs for low-impact fracture identified in this
population as age, family history of hip fracture, and prevalent
fragility fracture measured as HR (95% CI) per 1 SD increase (HR
0.61; 95% CI, 0.39 to 0.98). The HR also remained significant after
adjusting for lumbar spine BMD measured as HR (95% CI) per 1
SD increase (HR 0.47; 95% CI, 0.27 to 0.82) and hip BMD
measured as HR (95% CI) per 1 SD increase (HR 0.53; 95% CI, 0.32
to 0.88; Table 3). Women in the two highest DKK2 quartiles had a
fracture incidence rate of 14 per 1000 person-years, whereas
women in the two lowest DKK2 quartiles had a fracture
incidence rate of 32 per 1000 person-years (Fig. 2).
A high serum level of sFRP-1 was associated with an increased
risk of low-impact fracture measured as HR (95% CI) per 1 SD
increase (HR 1.45; 95% CI, 1.01 to 2.09). This association was
independent of CRFs measured as HR (95% CI) per 1 SD increase
(HR 1.62; 95% CI, 1.09 to 2.42), but dependent on BMD (Table 3).
Women in the two lowest sFRP-1 quartiles had a fracture
incidence rate of 11 per 1000 person-years, whereas women in
the two highest sFRP1 quartiles had a fracture incidence rate of
31 per 1000 person-years (Fig. 2).
Cox proportional hazard models showed no association
between serum level of SOST or DKK1 and fracture risk in senior
Fig. 1. Flowchart of study participants.
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Table 1. Crude Analysis of Sociodemographic and Economic Characteristics, Risk Factors for Fractures, and Health Status of Portuguese
Women Aged 65 Years With or Without Incident Fragility Fractures
All (n¼ 828)
No incident fragility fracture
(n¼ 669)
Incident fragility fracture
(n¼ 58) p value
Age (years)
65–69 270 (32.61%) 232 (34.68%) 17 (29.31%) 0.277
70–79 414 (50.00%) 339 (50.67%) 28 (48.28%)
80 144 (17.39%) 98 (14.65%) 13 (22.41%)
BMI (kg/m2)
Underweight 7 (0.86%) 5 (0.76%) 0 (0%) 0.866
Normal 205 (25.31%) 161 (24.51%) 14 (24.14%)
Overweight 358 (44.20%) 280 (42.62%) 28 (48.28%)
Obese 240 (29.63%) 211 (32.12%) 16 (27.59%)
Family history of hip fracture
Yes 51 (6.17%) 37 (5.54%) 8 (13.79%) 0.016a
No 776 (93.83%) 631 (94.46%) 50 (86.21%)
Current smoking
Yes 16 (1.93%) 14 (2.10%) 1 (1.72%) 0.849
No 811 (98.07%) 654 (97.90%) 57 (98.28%)
High alcohol intake (3 units/day)
Yes 14 (1.69%) 13 (1.95%) 1 (1.72%) 0.906
No 813 (98.31%) 655 (98.05%) 57 (98.28%)
Physical activity
Inactive 488 (84.87%) 443 (84.70%) 43 (86.00%) 0.807
Active 87 (15.13%) 80 (15.30%) 7 (14.00%)
Number of falls in previous 12 months 1.19 3.41 1.03 2.95 1.34 2.27 0.450
Use of glucocorticoids
Yes 30 (3.63%) 23 (3.44%) 4 (6.90%) 0.192
No 797 (96.37%) 645 (96.56%) 54 (93.10%)
Rheumatoid arthritis
Yes 13 (1.57%) 11 (1.65%) 1 (1.72%) 0.965
No 814 (98.43%) 657 (98.35%) 57 (98.28%)
Secondary osteoporosis
Yes 25 (3.02%) 20 (2.99%) 3 (5.17%) 0.370
No 802 (96.98%) 648 (97.01%) 55 (94.83%)
Chronic renal insufficiency (mL/min/1.73 m2)
eGFR <30 16 (2.51%) 13 (2.50%) 2 (4.76%) 0.392
eGFR 30 621 (97.49%) 506 (97.50%) 40 (95.24%)
Prevalent fragility fracture (self-reported)
Yes 172 (21.83%) 121 (18.94%) 26 (45.61%) <0.001a
No 616 (78.17%) 518 (81.06%) 31 (54.39%)
Prevalent fragility fracture site (self-reported)
Hip 10 (1.27%) 4 (0.63%) 2 (3.51%) 0.046a
Vertebral 11 (1.40%) 7 (1.10%) 2 (3.51%) 0.144
Nonhip/nonvertebral 121 (15.94%) 86 (13.85%) 16 (32.00%) 0.001a
FRAX score without BMD
10-year risk of major fracture
(mean SD)
9.62 6.85 9.00 6.04 12.83 10.71 <0.001a
10-year risk of hip fracture
(mean SD)
4.24 5.20 3.79 4.29 6.64 9.78 <0.001a
Lumbar spine BMD (g/cm2)
Lumbar spine BMD (mean SD) 0.99 0.21 1.00 0.21 0.97 0.21 0.471
Lumbar spine BMD (T score)
Osteoporosis (2.5) 69 (25.75%) 55 (23.81%) 6 (35.29%) 0.517
Osteopenia (>2.5 and <1) 89 (33.21%) 78 (33.77%) 4 (23.53%)
Normal (1) 110 (41.04%) 98 (42.42%) 7 (41.18%)
Axial BMD (T score)
Osteoporosis (2.5) 74 (27.31%) 59 (25.32%) 7 (38.89%) 0.398
Osteopenia (>2.5 and <1) 128 (47.23%) 111(47.64%) 6 (33.33%)
Normal (1) 69 (25.46%) 63 (27.04%) 5 (27.78%)
continued
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Table 1. (Continued)
All (n¼ 828)
No incident fragility fracture
(n¼ 669)
Incident fragility fracture
(n¼ 58) p value
Hip BMD (g/cm2)
Hip BMD (mean SD) 0.78 0.14 0.78 0.14 0.79 0.12 0.865
Hip BMD (T score)
Osteoporosis (2.5) 27 (9.93%) 21 (8.97%) 3 (16.67%) 0.464
Osteopenia (>2.5 and <1) 139 (51.10%) 119 (50.85%) 7 (38.89%)
Normal (1) 106 (38.97%) 94 (40.17%) 8 (44.44%)
Vitamin D (mmol/mL)
Deficiency (<10) 18 (2.96%) 15 (3.02%) 3 (7.50%) 0.341
Insufficiency (10 and <30) 212 (34.81%) 175 (35.28%) 13 (32.50%)
Normal (10) 379 (62.23%) 306 (61.69%) 24 (60.00%)
Bone turnover markers
CTX-I (ng/mL) 0.25 0.16 0.25 0.16 0.27 0.21 0.612
P1NP (ng/mL) 41.06 20.50 39.75 18.36 41.39 20.06 0.716
Osteocalcin (ng/mL) 3.77 2.46 3.60 2.28 4.05 1.85 0.412
PTH (ng/mL) 49.38 38.69 47.69 36.45 50.24 46.56 0.681
Serum levels of Wnt regulators
DKK2 (ng/mL) 7.79 2.86 7.75 2.75 6.86 2.39 0.144
sFRP-1 (ng/mL) 2.02 1.37 1.92 1.31 2.56 1.37 0.035a
SOST (pmol/L) 31.89 13.96 32.14 13.80 30.91 15.64 0.700
DKK1 (pmol/L) 132.24 76.48 136.76 76.74 118.16 81.00 0.311
Sample size is not constant. All: BMI (n¼ 810), family history of hip fracture (n¼ 827), current smoking (n¼ 827), high alcohol intake (n¼ 827), physical
activity (n¼ 575), number of falls in previous 12 months (n¼ 784), glucocorticoid use (n¼ 827), rheumatoid arthritis (n¼ 827), secondary osteoporosis
(n¼ 827), chronic renal insufficiency (n¼ 637), prevalent fragility fracture (n¼ 788), hip (n¼ 788), vertebral (n¼ 788), nonvertebral/nonhip (n¼ 759),
prevalent vertebral fracture (n¼ 318), FRAX (Fracture Risk Assessment Tool) major (n¼ 820), FRAX hip (n¼ 820), lumbar spine BMD (n¼ 268), hip BMD
(n¼ 271), vitamin D (n¼ 609), CTX-I (n¼ 289), P1NP (n¼ 287), osteocalcin (n¼ 291), PTHi (n¼ 592), SOST (n¼ 321), DKK1 (n¼ 290), DKK2 (n¼ 319), sFRP1
(n¼ 321). No incident fragility fracture: BMI (n¼ 657), family history of hip fracture (n¼ 668), current smoking (n¼ 668), high alcohol intake (n¼ 668),
physical activity (n¼ 523), number of falls in previous 12 months (n¼ 634), glucocorticoid use (n¼ 668), rheumatoid arthritis (n¼ 668), secondary
osteoporosis (n¼ 668), chronic renal insufficiency (n¼ 519), prevalent fragility fracture (n¼ 639), hip (n¼ 639), vertebral (n¼ 639), nonvertebral/nonhip
(n¼ 621), prevalent vertebral fracture (n¼ 276), FRAX major (n¼ 663), FRAX hip (n¼ 663), lumbar spine BMD (n¼ 231), hip BMD (n¼ 233), vitamin D
(n¼ 496), CTX-I (n¼ 241), P1NP (n¼ 241), osteocalcin (n¼ 243), PTHi (n¼ 481), SOST (n¼ 277), DKK1 (n¼ 249), DKK2 (n¼ 275), sFRP-1 (n¼ 276). Incident
fragility fracture: physical activity (n¼ 50), number of falls in previous 12 months (n¼ 56), chronic renal insufficiency (n¼ 42), prevalent fragility fracture
(n¼ 57), hip (n¼ 57), vertebral (n¼ 57), nonvertebral/nonhip (n¼ 50), prevalent vertebral fracture (n¼ 21), FRAX major (n¼ 57), FRAX hip (n¼ 57),
lumbar spine BMD (n¼ 17), hip BMD (n¼ 18), vitamin D (n¼ 40), CTX-I (n¼ 18), P1NP (n¼ 18), osteocalcin (n¼ 18), PTHi (n¼ 39), SOST (n¼ 20), DKK1
(n¼ 19), DKK2 (n¼ 21), sFRP1 (n¼ 21).
ap< 0.05.
Table 2. Correlations Between Serum Levels of DKK2, SOST, DKK1, and sFRP-1, and BMD Stratified by T-Score Groups


























0.0537 0.1415 0.0774 0.0042 0.0279 0.0081 0.0194 0.0034
sFRP1
(ng/mL)
0.2603c 0.0652 0.1864 0.4066c 0.1621a 0.0223 0.1912 0.1172
SOST
(pmol/L)
0.2944c 0.1569 0.0591 0.2099a 0.1917b 0.0244 0.1781 0.0053
DKK1
(pmol/L)
0.0162 0.1610 0.2916a 0.0385 0.1725b 0.1662 0.2235a 0.2083
Sample size is not constant. Lumbar spine BMD: SOST (n¼ 245), DKK1 (n¼ 220), DKK2 (n¼ 243), sFRP-1 (n¼ 244). Hip BMD: SOST (n¼ 247), DKK1
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women. Also, no associations were found between BTMs and
low-impact fracture incidence (Table 3).
FRAX score accurately predicts incident low-impact
fractures
Women designated at high fracture risk using FRAX score
(women with a 10-year risk of major fracture 11%)(38) had a
higher fracture incidence rate than women designated as low
fracture risk (women with a 10-year risk of major fracture<11%;
41 per 1000 person-years versus 18 per 1000 person-years;
p¼ 0.002) In fact, women with a 10-year risk of major fracture
11% had a 2.4-fold increased risk of low impact fractures (HR
2.37; 95% CI, 1.40 to 4.00) compared with women with a 10-year
risk of major fracture <11%.
Serum level of DKK2 improves fracture risk prediction
independently of FRAX score
Using a risk-stratified approach, the fracture incidence rate (per
1000 person-years) was calculated based on the combination
baseline 10-year risk of major fracture using FRAX score (without
Table 3.Crude and Adjusted Analysis of Associations Between Serum Levels of Wnt Regulators and Bone Turnover Markers and Incident
Fragility Fracture
Incidence fracture Continuous Per 1 SD increase
WNT regulators
DKK2 (ng/mL) HR p HR p
Crude 0.861 (0.738; 1.006) 0.059 0.655 (0.423; 1.016) 0.059
CRFs adjusted1 0.842 (0.714; 0.993) 0.041a 0.615 (0.386; 0.979) 0.041a
CRFsþ lumbar spine BMD adjusted2 0.767 (0.630; 0.933) 0.008a 0.471 (0.271; 0.821) 0.008a
CRFsþhip BMD adjusted3 0.798 (0.665; 0.958) 0.015a 0.529 (0.316; 0.885) 0.015a
sFRP-1 (ng/mL) HR p HR p
Crude 1.318 (1.008; 1.722) 0.043a 1.453 (1.011; 2.087) 0.043a
CRFs adjusted1 1.431 (1.067; 1.918) 0.017a 1.624 (1.092; 2.416) 0.017a
CRFsþ lumbar spine BMD adjusted2 1.265 (0.891; 1.796) 0.188 1.375 (0.856; 2.209) 0.188
CRFsþhip BMD adjusted3 1.329 (0.971; 1.819) 0.075 1.470 (0.961; 2.248) 0.075
SOST (pmol/L) HR p HR p
Crude 1.001 (0.970; 1.033) 0.939 1.017 (0.661; 1.564) 0.939
CRFs adjusted1 1.007 (0.975; 1.039) 0.677 1.097 (0.709; 1.696) 0.677
CRFsþ lumbar spine BMD adjusted2 0.999 (0.957; 1.043) 0.956 0.983 (0.545; 1.774) 0.956
CRFsþhip BMD adjusted3 0.989 (0.949; 1.030) 0.578 0.853 (0.488; 1.491) 0.578
DKK1 (pmol/L) HR p HR p
Crude 0.998 (0.990; 1.003) 0.512 0.845 (0.511; 1.396) 0.512
CRFs adjusted1 0.996 (0.989; 1.004) 0.307 0.743 (0.421; 1.313) 0.307
CRFsþ lumbar spine BMD adjusted2 0.993 (0.983; 1,003) 0.151 0.588 (0.285; 1.214) 0.151
CRFsþhip BMD adjusted3 0.991 (0.982; 1.000) 0.078 0.510 (0.241; 1.079) 0.078
Bone turnover markers
CTX-I (ng/mL) HR p HR p
Crude 2.076 (0.197; 21.862) 0.543 1.126 (0.768; 1.652) 0.543
CRFs adjusted1 2.687 (0.241; 29.973) 0.422 1.175 (0.793; 1.740) 0.422
CRFsþ lumbar spine BMD adjusted2 1.469 (0.001; 3849.7) 0.924 1.065 (0.295; 3.836) 0.924
CRFsþhip BMD adjusted3 1.024 (0.001; 1544.9) 0.995 1.004 (0.305; 3.306) 0.995
P1NP (ng/mL) HR p HR p
Crude 1.005 (0.981; 1.030) 0.679 1.111 (0.679; 1.813) 0.679
CRFs adjusted1 1.010 (0.985; 1.035) 0.434 1.217 (0.744; 1.992) 0.434
CRFsþ lumbar spine BMD adjusted2 1.032 (0.965; 1.104) 0.361 1.885 (0.484; 7.346) 0.361
CRFsþhip BMD adjusted3 1.025 (0.966; 1.088) 0.413 1.654 (0.496; 5.521) 0.413
Osteocalcin (ng/mL) HR p HR p
Crude 1.075 (0.925; 1.250) 0.346 1.191 (0.828; 1.713) 0.346
CRFs adjusted1 1.091 (0.936; 1.272) 0.266 1.234 (0.852; 1.787) 0.266
CRFsþ lumbar spine BMD adjusted2 1.299 (0.963; 1.751) 0.087 1.879 (0.913; 3.868) 0.913
CRFsþhip BMD adjusted3 1.123 (0.870; 1.450) 0.373 1.324 (0.714; 2.452) 0.373
1Adjusted for age, family history of hip fracture, and prevalent fragility fracture (self-reported).
2Adjusted for age, family history of hip fracture, prevalent fragility fracture (self-reported), and lumbar spine BMD.
3Adjusted for age, family history of hip fracture, prevalent fragility fracture (self-reported), and hip BMD. Sample size is not constant. SOST: crude
(n¼ 529), adjusted1 (n¼ 496), adjusted2 (n¼ 368), adjusted3 (n¼ 371). DKK1: crude (n¼ 476), adjusted1 (n¼ 443), adjusted2 (n¼ 323), adjusted3
(n¼ 320). DKK2: crude (n¼ 527), adjusted1 (n¼ 494), adjusted2 (n¼ 366), adjusted3 (n¼ 369). sFRP-1: crude (n¼ 529), adjusted1 (n¼ 496), adjusted2
(n¼ 366), adjusted3 (n¼ 369). CTX-I: crude (n¼ 450), adjusted1 (n¼ 420), adjusted2 (n¼ 138), adjusted3 (n¼ 138). P1NP: crude (n¼ 451), adjusted1
(n¼ 421), adjusted2 (n¼ 138); adjusted3 (n¼ 140). Osteocalcin: crude (n¼ 455), adjusted1 (n¼ 425), adjusted2 (n¼ 138), adjusted3 (n¼ 140).
CRFs¼ clinical risk factors.
ap< 0.05.
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BMD) and serum level of DKK2 (Fig. 3). Low serum levels of DKK2
can enhance fracture risk prediction in women considered as
low risk of fracture by FRAX score. Women with low serum levels
of DKK2 (33 per 1000 person-years) had a higher fracture
incidence rate than women with high serum levels of DKK2 (9
per 1000 person-years; p< 0.038; Fig. 3).
Discussion
The present study, conducted in a population-based cohort of
senior women, showed that low serum level of DKK2 predicted
low-impact fractures, independently of BMD and CRFs for
fracture. For every 1 SD decrease in DKK2, fracture risk increased
by approximately 1.5-fold. Serum levels of DKK2 were not
associated with lumber spine or hip BMD. Our results need to be
further investigated in a larger study with a longer follow-up
period.
DKK molecules are Wnt-b-catenin signaling regulators.(40)
DKK2 is mainly expressed by osteoblasts and has a dual effect on
Wnt-b-catenin signaling. It is a potent antagonist of Wnt-b-
catenin signaling, by binding to low-density lipoprotein
receptor-related proteins 5 and 6, and by controlling osteoblast
differentiation. However, it also has a weak agonistic effect.
Overall, DKK2 acts as a fine-tuning regulator of osteoblast
Fig. 2. Association between DKK2 and sFRP-1 quartiles with incident fracture rate (per 1000 person-years). Women in the two highest DKK2 quartiles
had a significantly lower fracture incidence than women in the two lowest DKK2 quartiles. Women in the two lowest sFRP-1 quartiles had significantly
lower fracture incidence than women in the two highest sFRP-1 quartiles.
Fig. 3. Relationship between DKK2 quartiles and Fracture Risk Assessment (FRAX) tool score. Women in the two lowest DKK2 quartiles had the highest
fracture incidence rate independently of being under or above the cutoff for 10-year major fracture risk (ie, 11%).
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terminal differentiation and function through Wnt signaling
dependent and independent mechanisms, leading to an
enhancement of mineralization.(20) DKK2 is upregulated in
osteoarthritis subchondral bone (with local high bone mass); in
vitro upregulation of DKK2 in osteoblasts increases their ability
to form mineralized nodules.(41) By contrast, DKK2 deficiency in
vivo leads not only to mineralization disturbances and bone
fragility, but also to a moderate reduction in bone mass.(20)
These results are in line with our present findings showing that a
decreased serum level of DKK2 was associated with bone
fragility fracture, but not with lumbar spine and hip BMD. This
may be because osteoblast mineralization disturbances, sig-
nalled by low levels of DKK2, lead to bone nanoarchitecture
disorganization and fragility, independently of bone mass
loss.(42–44)
DKK1 is a key inhibitor of LRP5/6 and of Wnt-b-catenin
signaling, and is mainly expressed by osteocytes. It is therefore
expected that an increased DKK-1 expression will be associated
with a decreased Wnt activity and bone mass.(14) In line with
that, we observed a negative correlation between serum levels
of DKK1 and BMD, similar to what was previously reported.(45,46)
However, we found no association between DKK1 serum levels
and incident fracture. In line with our results, a study from Korea
did not find an association of serum levels of DKK1 and prevalent
osteoporotic fractures.(25) In contrast, in a cross-sectional study
in Sweden, serum levels of DKK1 were increased in patients with
a fresh hip fracture when compared with healthy volunteers.(47)
sFRP-1 and SOST are also Wnt-b-catenin signaling inhibitors.
Overexpression of sFRP-1 in human osteoblasts accelerates the
rate of cell death, and thus inhibits bone formation.(18,48)
Concordantly, we found that high levels of sFRP-1 were
associated with incident low-impact fracture, independent of
CRFs for fracture. However, this association was not indepen-
dent of BMD. Surprisingly, in our study, high serum levels of
sFRP-1 and SOST were significantly associated with high lumbar
spine and hip BMD. Given that sFRP-1 and SOST inhibit
osteoblast proliferation and maturation, we would have
expected a negative correlation with BMD. Other studies also
found the same paradoxical results.(16,23,49) Of interest, when we
analyzed the association between serum levels of SOST and
sFRP-1 and BMD categorized by T score, we confirmed the
existence of correlations in women with normal BMD, but not
with osteopenia or osteoporosis. One possible explanation is
that in healthy individuals, normal BMD is maintained through
local downregulation of Wnt inhibitors in association with high
systemic serum levels of SOST and sFRP-1. In agreement with
this possibility, the serum level of SOST is higher in men (who
have a lower global fracture risk) than in women.(50) However, in
pathological situations, as in individuals with bone fragility and a
high risk of fracture, this regulation system is disrupted, and
serum levels of Wnt regulators are associated with osteoblast
dysfunction, bone fragility, and fracture, as our results showed.
In our study, serum levels of SOST were not significantly
associated with incident low-impact fracture. Similarly, the
OFELY study followed 572 postmenopausal women for 6 years
and reported no association between serum level of SOST with
incident nonvertebral and clinical vertebral fractures.(22) Amrein
and colleagues also found no association between SOST serum
level with hip and other nonvertebral fractures in institutional-
ized elderly women.(51) By contrast, the Center of Excellence for
Osteoporosis Research Study followed 707 postmenopausal
women for 5 years and showed that a high serum SOST level is
associated with an increased risk of vertebral and nonvertebral
low-impact fracture.(24) Concordantly, Arasu et al. also found
that serum levels of SOST were associated with hip fractures
among women aged 65 years or older.(23)
We also found no associations between serum levels of BTMs
(P1NP, CTX-I, and osteocalcin) and fragility fractures. Although
several studies have proposed BTMs as fracture risk predictors,
their results are not conclusive.(10,52–55) A recent meta-analysis
reports a modest association between CTX-I and fragility
fracture, although this association is not independent of
BMD.(10) These ambiguous study results probably contribute
to the low acceptance and utility of BTMs in clinical practice and
re-enforce the need to find alternative markers of fragility
fracture risk.
This study has some limitations. First, fragility fractures were
self-reported, which is less accurate than clinically verified
vertebral fractures, leading to the underestimation of their
prevalence(56); however, the overall performance of self-
reported fragility fractures is respectable.(30–32) Second, the
number of incident fractures was relatively low because of a
short follow-up duration (2.3 1.0 years). DKK2 were measured
in a randomized subsample (n¼ 319) of our population
(N¼ 828) and 19 incident fractures were recorded in this
subsample. Hence, these results must be confirmed in other
cohorts with more participants and longer follow-up periods.
Nevertheless, several strengths of this study should also be
acknowledged. Our data came from a large, representative
sample of the Portuguese adult population and participants
were examined by rheumatologists at baseline. Furthermore,
different fragility fractures and health-related measurements
were captured, providing relevant information about risk
factors.
In conclusion, we report that low serum levels of DKK2 predict
the risk of low-impact fractures, independently of BMD and CRFs
and thus should be explored as a potential noninvasive marker
of fragility fracture risk. High serum levels of sFRP-1 were
significantly associated with fracture, although this association
was not independent of BMD. Both SOST and DKK1 were
associated with BMD, but not with incident fracture, although
the number of new fractures recorded may not have allowed the
detection of these latter associations. These results indicate that
serum DKK2 and sFRP1 may predict low-impact fracture. The low
number of incident fractures recorded is a limitation; hence,
serum levels of Wnt regulators should be further studied in other
populations as potential noninvasive markers of fragility
fractures.
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